Help me Challenge Cancer!
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your support, we are saving more lives. #OneTeamOneFight
Related Articles
Tumor Treating Fields Extend OS for Patients With Locally Advanced Pancreatic Cancer
The addition of tumor treating fields to first-line chemotherapy can extend overall survival without increasing systemic toxicity among patients with locally advanced pancreatic cancer, according…
First-Line Sacituzumab Govitecan + Pembro Significantly Improves PFS Over Chemo + Pembro in PD-L1–Positive TNBC
According to results from the phase 3 ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab demonstrates a significant improvement in progression-free survival compared with chemotherapy plus pembrolizumab…
Sylvester Comprehensive Cancer Center Recaps ASCO 2025 Participation – OncoDaily
Sylvester Comprehensive Cancer Center Recaps ASCO 2025 Participation / ASCO25, cancer, cancer care, OncoDaily, Oncology, Sylvester Comprehensive Cancer Center
JCO Global Oncology’s New Editor-In-Chief Dr. Katherine Van Loon to Champion Enhanced Access and Representation in Cancer Research
Dr. Katherine Van Loon is committed to addressing the increasing global cancer burden by elevating diverse voices and research focused on expanding access to cancer…
CAN-2409 Viral Immunotherapy Boosts Long-Term Benefits With Manageable Toxicity in Newly Diagnosed Localized Prostate Cancer
CAN-2409 plus valacyclovir significantly improves disease-free survival compared with placebo plus valacyclovir combined with standard external beam radiation therapy with or without short-course androgen deprivation…
Nivolumab + Relatlimab Fails to Improve RFS in Resectable Stage III/IV Melanoma in Phase 3 RELATIVITY-098 Trial
Combination nivolumab and relatlimab does not improve relapse-free survival over nivolumab monotherapy in patients with completely resected stage III/IV melanoma, according to results of the…
Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM
Initial results from part 1 of the phase 3 MagnetisMM-6 study show that elranatamab in combination with lenalidomide and daratumumab yields a high response rate…
DESTINY-Breast09: Trastuzumab Deruxtecan Plus Pertuzumab Sets New First-Line Benchmark in HER2-Positive Metastatic Breast Cancer
First-line treatment with trastuzumab deruxtecan plus pertuzumab extends progression-free survival by more than 1 year compared with standard-of-care taxane plus trastuzumab/pertuzumab, according to initial results…
Podcast: Day 4: Top Takeaways From ASCO25
Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer…